Navigation Links
LCA-Vision to Present at the Bank of America 2008 Health Care Conference
Date:5/9/2008

CINCINNATI, May 9 /PRNewswire-FirstCall/ -- LCA-Vision Inc. (Nasdaq: LCAV), a leading provider of laser vision correction services under the LasikPlus(R) brand, announced today that its Chief Executive Officer, Steve Straus, will present at the Bank of America 2008 Health Care Conference on Wednesday, May 14, 2008 at 2:00 p.m. PT at the Four Seasons Hotel in Las Vegas, Nevada. The live and archived webcast will be available at the Investor Relations section of LCA-Vision's website at http://www.lasikplus.com/bankofamerica/.

About LCA-Vision Inc./LasikPlus(R)

LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus(R) brand, operates 76 LasikPlus(R) fixed-site laser vision correction centers in 33 states and 59 markets in the United States and a joint venture in Canada. Additional company information is available at http://www.lca-vision.com and http://www.lasikplus.com.

For Additional Information

Patricia Forsythe

V.P. Investor Relations

513-792-5629

pforsythe@lca.com


'/>"/>
SOURCE LCA-Vision Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against LCA-Vision Inc.
2. LCA-Vision Announces Upcoming Investment Community Events
3. LCA-Vision Reports Fourth Quarter and Full-Year 2007 Financial Results
4. LCA-Vision Announces Quarterly Dividend Payment
5. LCA-Vision Announces the Opening of its 74th LasikPlus Vision Center in Des Moines, Iowa
6. LCA-Vision Announces the Opening of its 75th LasikPlus(R) Vision Center in Tulsa, Oklahoma
7. LCA-Vision Announces the Opening of its 76th LasikPlus(R) Vision Center in Woodbridge, New Jersey
8. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
9. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
10. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
11. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...ns of influenza activity 2-4 weeks in advance in t... // Though there are outbreaks of influenza any ti...e announced which would act as a caution to people...es like vaccination. In a prediction market, peopl...
..., also called magic mushrooms can effectively redu...OCD), according to a study// by University of Ariz...es like psilocybin, psilocin, or muscimol. The fir...approved) was outlawed in 1970, according to AP re...
...ntiretroviral treatment (HAART), people with HIV m...ncies and abnormalities. // In two different stud...n the Department of Public Health and Family Medic...cine, and colleagues examined the incidence of met...
...lood to the part of the brain affected is interrup...iously damaged or die, impairing local brain funct... of a stroke, new blood vessels begin to form, and...ns migrate long distances to the damaged area to a...
Other Medicine News:Health News:The Outbreak of Influenza is Now Predicted 2Health News:HIV Treatments Improve Health, but Nutritional Issues Remain 2Health News:HIV Treatments Improve Health, but Nutritional Issues Remain 3Health News:Cellular Cues Identified for Stroke Recovery 2
(Date:9/3/2008)...s Phase 3 Plans with FDA, PRINCETON, N.J., Sept. ...ced today that it successfully completed two key c... new, innovative low-dose, once-weekly,contracept...rnal product,code AG-200-15. The Phase 2b safety a...point of ovulation suppression, cycle control and ...
(Date:9/3/2008)...trong Evidence Pycnogenol(R) Lowers Joint, Pain, S...lowing Cessation of th... According to the Center for,Disease Control (CDC)...s,is on the rise. A new study published in the Au...nogenol(R), bark extract from the French maritime ...
(Date:9/3/2008)...wswire-FirstCall/ -- A sub-analysis of,the TRITON-...prasugrel,compared with clopidogrel significantly ... (7.4 percent vs. 9.7 percent, p<0.0001), regardle...of an artery-opening,procedure known as percutaneo...d spontaneously during the longer-term maintenance...
(Date:9/2/2008)...-FirstCall/ --, - This Analysis Showed That Multa... 34% in Patients With Atrial Fibrillation or Atria...otic Therapy, The results of a post-hoc analysis ...oday at the clinical trial update session of the E...nich, Germany. Previous results,from the landmark ...
Breaking Medicine Technology:Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 2Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 3Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 6Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Sinexus Welcomes New CEO and Completes Series B 21149 1Sinexus Welcomes New CEO and Completes Series B 21149 2Sinexus Welcomes New CEO and Completes Series B 21149 3Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi Center Radiation Therapy Systems Agreement 21144 1Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi Center Radiation Therapy Systems Agreement 21144 2Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi Center Radiation Therapy Systems Agreement 21144 3Summer is for Sleeping 3F Exhausted Americans Challenged to Sleep in on Longest Day of the Year 21139 1Summer is for Sleeping 3F Exhausted Americans Challenged to Sleep in on Longest Day of the Year 21139 2Summer is for Sleeping 3F Exhausted Americans Challenged to Sleep in on Longest Day of the Year 21139 3Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 1Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 2Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 3Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 4
...zed phase II/III clinical trial,anticipated later ...tCall/ -- Cell,Therapeutics, Inc. (CTI) announced ...nstrate that treatment with pixantrone (BBR,2778) ...ty, while,doxorubicin and mitoxantrone induced sig...cardiac side effects of equiactive doses,of pixant...
...WIRE)--Jun 26, 2007 - Sirtris,Pharmaceuticals, Inc...sed on discovering and developing small molecule d...hat activation of SIRT1, a,member of the sirtuin f...rodegenerative diseases such as Alzheimer,s Diseas...ls. These findings,appear in an article published ...
Other Medicine Technology:Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 2Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 3Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 4Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 5Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 6Resveratrol Studies Suggest Broad Implications for SIRT1 Activation,in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease 2Resveratrol Studies Suggest Broad Implications for SIRT1 Activation,in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease 3
High sensitive, specific one step immunochromatographic assay for human infectious disease
Span Diagnostics Limited
Malaria (P. fal.) Ag Rapid Test
OptiMAL is a malaria test, for diagnosis and therapy control of an infection by Plasmodium species (Malaria).
Medicine Products: